Cited by 209Autism Spectrum Disorder ResearchGenetics and Neurodevelopmental DisordersGenomics and Rare Diseases

Autism spectrum disorder and attention deficit hyperactivity disorder have a similar burden of rare protein-truncating variants

Open access
iPSYCH-Broad Consortium, Satterstrom, F. Kyle, Walters, Raymond K., Singh, Tarjinder, Wigdor, Emilie M., Lescai, Francesco, Demontis, Ditte, Kosmicki, Jack A. +15 more·2019·Nature Neuroscience

Abstract

The exome sequences of approximately 8,000 children with autism spectrum disorder (ASD) and/or attention deficit hyperactivity disorder (ADHD) and 5,000 controls were analyzed, finding that individuals with ASD and individuals with ADHD had a similar burden of rare protein-truncating variants in evolutionarily constrained genes, both significantly higher than controls. This motivated a combined analysis across ASD and ADHD, identifying microtubule-associated protein 1A (MAP1A) as a new exome-wide significant gene conferring risk for childhood psychiatric disorders. Using samples from the Danish Neonatal Screening Biobank, children with ASD and children with ADHD were found to have similar, significantly increased rates of rare protein-truncating variants in evolutionarily constrained genes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41593-019-0527-8

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Children with autism or ADHD show more rare genetic mutations than controls.

    “those with ASD and those with ADHD had an increased rate of rare genetic mutations compared with controls”

    From The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder (2021) · cites this paper as Satterstrom et al., 2019

    The Abstract and Results (‘Rates of constrained rare variation’; page not provided) report that children with ASD and children with ADHD had higher burdens than controls of rare protein-truncating variants in constrained genes. The claim omits that restriction and implies an increased rate of rare genetic mutations generally, which the paper does not establish. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • The de novo mutation rate in autistic individuals from the SPARK and SSC cohorts may be generalizable.

    “implying that the de novo mutation rate in autistic individuals from the SPARK and SSC cohorts may be generalizable.”

    From Genetic correlates of phenotypic heterogeneity in autism (2022) · cites this paper as [100]

  • A previous study demonstrated that the mutation rate for rare protein-truncating variants is similar between autistic individuals and siblings from the SSC and autistic individuals and population controls from the iPSYCH sample in Denmark, which does not have a participation bias.

    “However, a previous study has demonstrated that the mutation rate for rare protein-truncating variants is similar between autistic individuals and siblings from the SSC and autistic individuals and population controls from the iPSYCH sample in Denmark, which does not have a participation bias100”

    From Genetic correlates of phenotypic heterogeneity in autism (2022) · cites this paper as [100]

  • Many types of ASD-associated de novo variants are observed more frequently in female cases.

    “Many types of ASD-associated de novo variants are observed more frequently in female cases.4, 5, 6, 7, 8, 9, 10, 11, 12, 13”
  • Genetic studies of de novo variants have consistently supported a female protective effect against ASD.

    “The possibility of a “female protective effect” (FPE) against ASD has been described extensively and has received consistent support from the results of genetic studies of de novo variants.4, 5, 6, 7, 8, 9, 10, 11, 12, 13”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [19]Neyman J & Scott E On the use of c(α) optimal tests of composite hypothesis. Bulletin of the International Statistical Institute 41, 477– 497 (1966).

Cited by

Sorted by citations

Authors
iPSYCH-Broad Consortium, Satterstrom, F. K., Walters, R. K., Singh, T., Wigdor, E. M., Lescai, F., Demontis, D., Kosmicki, J. A., Grove, J., Stevens, C., Bybjerg-Grauholm, J., Bækvad-Hansen, M., Palmer, D. S., Maller, J. B., Nordentoft, M., Mors, O., Robinson, E. B., Hougaard, D. M., Werge, T. M., Bo Mortensen, P., Neale, B. M., Børglum, A. D., & Daly, M. J.
Affiliations
  • Broad Institute (US)
  • Aarhus University (DK)
  • University of Copenhagen (DK)
  • Aarhus University Hospital (DK)
  • Statens Serum Institut (DK)
Corresponding author
  • Satterstrom, F. Kyle
  • Børglum, Anders D.
  • Daly, Mark J.
Venue
Nature Neuroscience
Published
2019-11-25
Volume
22
Issue
12
Pages
1961-1965
ISSN
  • 1097-6256 (ISSN-L)
  • 1546-1726
OpenAlex
W2989783162
Cited by
209
References
31
Citations by year
2026: 14 · 2025: 24 · 2024: 26 · 2023: 36 · 2022: 39 · 2021: 33 · 2020: 32 · 2019: 3 · 2018: 2
FWCI
15.44
Type
journal article
Language
en
Open access
Locations
  • Nature Neuroscience (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Lundbeckfonden (R155-2014-1724, R248‐2017‐2003)
  • Novo Nordisk Fonden (NNF 16OC0022018)
  • National Institutes of Health (5u01mh094432-04)
  • National Institute of Mental Health (U01MH109539, U01 MH094432, U01MH100229, U01MH109536, U01MH111660)
  • National Human Genome Research Institute (T32HG002295)
Topics
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords
autism spectrum disorder, attention deficit hyperactivity disorder, genetic burden, MAP1A, child psychopathology, risk genes, exome sequencing
MeSH terms
Autism Spectrum Disorder, Attention Deficit Disorder with Hyperactivity, Female, Humans, Male, Microtubule-Associated Proteins, Genetic Variation, Case-Control Studies, Genetic Predisposition to Disease, Exome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review